Biesenbach G - Search Results

1

Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients.

Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G. Biesenbach G, et al. Diabet Med. 2003 Aug;20(8):642-5. doi: 10.1046/j.1464-5491.2003.01025.x. Diabet Med. 2003. PMID: 12873291

2

Erythropoietin requirement in patients with type 2 diabetes mellitus on maintenance hemodialysis therapy.

Biesenbach G, Schmekal B, Eichbauer-Sturm G, Janko O. Biesenbach G, et al. Wien Klin Wochenschr. 2004 Dec 30;116(24):844-8. doi: 10.1007/s00508-004-0286-7. Wien Klin Wochenschr. 2004. PMID: 15690969

3

Metabolic control in insulin-treated type 2-diabetic patients aged over 80 years and without participation in a structured diabetic teaching program.

Sedlak M, Raml A, Schmekal B, Grafinger P, Biesenbach G. Sedlak M, et al. Among authors: biesenbach g. Wien Med Wochenschr. 2005 Jan;155(1-2):26-9. doi: 10.1007/s10354-004-0133-5. Wien Med Wochenschr. 2005. PMID: 15773741 Clinical Trial.

4

Long-term impact of chronic hemodialysis on glycemic control and serum lipids in insulin-treated type 2-diabetic patients.

Loipl J, Schmekal B, Biesenbach G. Loipl J, et al. Among authors: biesenbach g. Ren Fail. 2005;27(3):305-8. Ren Fail. 2005. PMID: 15957547

5

Improvement of glycemic control after a 3-5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy.

Biesenbach G, Grafinger P, Raml A. Biesenbach G, et al. Wien Klin Wochenschr. 2006 Sep;118(17-18):543-8. doi: 10.1007/s00508-006-0656-4. Wien Klin Wochenschr. 2006. PMID: 17009067 Clinical Trial.

6

Rate of decline of GFR and progression of vascular disease in type 2 diabetic patients with diabetic or vascular nephropathy during the last three years before starting dialysis therapy.

Biesenbach G, Schmekal B, Pieringer H, Janko O. Biesenbach G, et al. Kidney Blood Press Res. 2006;29(5):267-72. doi: 10.1159/000096175. Epub 2006 Oct 11. Kidney Blood Press Res. 2006. PMID: 17035711

7

[Risk for hyperkalemia during long-term treatment with angiotensin-converting enzyme inhibitors in insulin-dependent type 2 diabetics in relation to the glomerular filtration rate].

Raml A, Schmekal B, Grafinger P, Biesenbach G. Raml A, et al. Among authors: biesenbach g. Dtsch Med Wochenschr. 2001 Nov 23;126(47):1327-30. doi: 10.1055/s-2001-18569. Dtsch Med Wochenschr. 2001. PMID: 11719857 German.

8

Impact of kidney transplantation on glycemic control and cardiovascular risk factors in insulin-treated diabetic patients receiving cyclosporine: a longitudinal study.

Schmekal B, Biesenbach G, Janko O. Schmekal B, et al. Among authors: biesenbach g. Transplant Proc. 2004 Dec;36(10):3012-5. doi: 10.1016/j.transproceed.2004.10.083. Transplant Proc. 2004. PMID: 15686683

9

Weight gain and insulin requirement in type 2 diabetic patients during the first year after initiating insulin therapy dependent on baseline BMI.

Biesenbach G, Raml A, Alsaraji N. Biesenbach G, et al. Diabetes Obes Metab. 2006 Nov;8(6):669-73. doi: 10.1111/j.1463-1326.2005.00552.x. Diabetes Obes Metab. 2006. PMID: 17026491

10

Predialysis management and predictors for early mortality in uremic patients who die within one year after initiation of dialysis therapy.

Biesenbach G, Hubmann R, Janko O, Schmekal B, Eichbauer-Sturm G. Biesenbach G, et al. Ren Fail. 2002 Mar;24(2):197-205. doi: 10.1081/jdi-120004096. Ren Fail. 2002. PMID: 12071593 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

133 results

Search Page

Filters